113 related articles for article (PubMed ID: 31423895)
21. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Sharma NL; Groselj B; Hamdy FC; Kiltie AE
BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
[TBL] [Abstract][Full Text] [Related]
22. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
23. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
[TBL] [Abstract][Full Text] [Related]
24. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
25. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
26. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.
Singh BN; Zhou H; Li J; Tipton T; Wang B; Shao G; Gilbert EN; Li Q; Jiang SW
Future Oncol; 2011 Dec; 7(12):1415-28. PubMed ID: 22112317
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
Exp Cell Res; 2024 Jun; 439(1):114055. PubMed ID: 38704080
[TBL] [Abstract][Full Text] [Related]
28. Platinum Resistance in Ovarian Cancer: Role of DNA Repair.
Damia G; Broggini M
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669514
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic therapy for ovarian cancer: promise and progress.
Moufarrij S; Dandapani M; Arthofer E; Gomez S; Srivastava A; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Clin Epigenetics; 2019 Jan; 11(1):7. PubMed ID: 30646939
[TBL] [Abstract][Full Text] [Related]
30. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
31. Deregulated expression of HDAC3 in colorectal cancer and its clinical significance.
Nemati M; Ajami N; Estiar MA; Rezapour S; Gavgani RR; Hashemzadeh S; Kafil HS; Sakhinia E
Adv Clin Exp Med; 2018 Mar; 27(3):305-311. PubMed ID: 29558042
[TBL] [Abstract][Full Text] [Related]
32. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway.
Han Y; Song C; Wang J; Tang H; Peng Z; Lu S
Mol Carcinog; 2018 Jun; 57(6):722-734. PubMed ID: 29436749
[TBL] [Abstract][Full Text] [Related]
33. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma.
Zhou Y; Wang L; Ban X; Zeng T; Zhu Y; Li M; Guan XY; Li Y
Oncogene; 2018 Feb; 37(8):1086-1094. PubMed ID: 29106393
[TBL] [Abstract][Full Text] [Related]
34. Epigenetics in ovarian cancer.
Natanzon Y; Goode EL; Cunningham JM
Semin Cancer Biol; 2018 Aug; 51():160-169. PubMed ID: 28782606
[TBL] [Abstract][Full Text] [Related]
35. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
Zagni C; Floresta G; Monciino G; Rescifina A
Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases.
Qiu X; Xiao X; Li N; Li Y
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():60-72. PubMed ID: 27614213
[TBL] [Abstract][Full Text] [Related]
37. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
38. Inside HDACs with more selective HDAC inhibitors.
Roche J; Bertrand P
Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
